Executive Committee: IRLAB Therapeutics AB

Manager
Positions heldSince
Kristina Torfgård

Kristina Torfgård

63 year

Chief Executive Officer 31/07/2024
Nicholas Waters

Nicholas Waters

64 year

Chief Tech/Sci/R&D Officer 30/06/2022
Founder 31/12/2012
Investor Relations Contact 31/12/2012
Public Communications Contact 31/12/2012
Clas Sonesson

Clas Sonesson

65 year

Chief Tech/Sci/R&D Officer 31/12/2015
Founder 31/12/2012
Joakim Tedroff

Joakim Tedroff

65 year

Chief Tech/Sci/R&D Officer 31/12/2015
Peder Svensson

Peder Svensson

64 year

Chief Tech/Sci/R&D Officer 31/12/2012
Gustaf Albért

Gustaf Albért

58 year

Director of Finance/CFO 16/11/2025

Composition of the Board of Directors: IRLAB Therapeutics AB

Director
CommitteesSince
Carola Elisabet Lemne

Carola Elisabet Lemne

68 year

Audit Committee 19/02/2023
Nominating Committee 19/11/2025
Compensation Committee Chair 19/02/2023
Compensation Committee 31/12/2021
Rein Piir

Rein Piir

68 year

Audit Committee
Compensation Committee
Gunnar Olof Olsson

Gunnar Olof Olsson

73 year

Audit Committee 19/02/2023
Christer Nordstedt

Christer Nordstedt

64 year

Compensation Committee 31/12/2022
Veronica Wallin

Veronica Wallin

40 year

Director/Board Member 31/12/2022
Independent Dir/Board Member 31/12/2022

Former Officers and Directors: IRLAB Therapeutics AB

Insider
Positions held
SinceUntil
Roy Peter Jonebrant
Roy Peter Jonebrant
Director of Finance/CFO 31/08/2025 06/11/2025
Erik Viktor Siewertz
Erik Viktor Siewertz
Chief Operating Officer 31/12/2015 31/05/2017
Director of Finance/CFO 31/05/2017 30/08/2025
Public Communications Contact 31/12/2012 30/08/2025
Catharina Gustafsson Wallich
Catharina Gustafsson Wallich
Director/Board Member 31/12/2021 10/06/2025
Independent Dir/Board Member 31/12/2021 10/06/2025
Daniel Johnsson
Daniel Johnsson
Director/Board Member 31/12/2022 10/06/2025
Richard Stuart Godfrey
Richard Stuart Godfrey
Chief Executive Officer 30/06/2022 19/02/2023
An van Es-Johansson
An van Es-Johansson
Director/Board Member 30/04/2022 31/01/2023
Independent Dir/Board Member 30/04/2022 31/01/2023
Maria Jalmelid
Maria Jalmelid
Chief Tech/Sci/R&D Officer 31/12/2017 01/01/2023
Corporate Officer/Principal 31/12/2017 -
Alf Gunnar Martin Nicklasson
Alf Gunnar Martin Nicklasson
Director/Board Member 31/12/2020 -
Independent Dir/Board Member 31/12/2020 -
Bo Jacob Testor
Bo Jacob Testor
Director/Board Member 31/12/2015 15/05/2018
Independent Dir/Board Member 31/12/2015 15/05/2018
John Wakely
John Wakely
Director/Board Member 15/05/2018 -
Hans-Peter Albert Ostler
Hans-Peter Albert Ostler
Director/Board Member 31/12/2015 15/05/2017
Independent Dir/Board Member 31/12/2015 15/05/2017
Lars Ivar Robert Adlersson
Lars Ivar Robert Adlersson
Director/Board Member 15/05/2017 -
Independent Dir/Board Member 15/05/2017 -
Hans-Olov Olsson
Hans-Olov Olsson
Director/Board Member 05/05/2017 -
Independent Dir/Board Member 05/05/2017 -
Eva Lindgren
Eva Lindgren
Director/Board Member 31/12/2015 -
Independent Dir/Board Member 31/12/2015 -
Cecilia Tivert Stenberg
Cecilia Tivert Stenberg
Comptroller/Controller/Auditor - -
Director of Finance/CFO 31/12/2015 -
Human Resources Officer 31/12/2015 -
Jan Anders Vedin
Jan Anders Vedin
Director/Board Member 19/02/2023 -
Chairman 31/12/2015 19/02/2023
Independent Dir/Board Member 31/12/2015 -
Lena Margareta Torlegård
Lena Margareta Torlegård
Director/Board Member - -

Age distribution of managers

Parity Men Women

Male11
Female1

Of which Executive Committee

Male6
Female0

Of which Directors

Male4
Female1
Logo IRLAB Therapeutics AB
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Employees
31

Departures of Key Persons

Richard Stuart Godfrey
-
Richard Stuart Godfrey

Chief Executive Officer

30/06/2022 19/02/2023

Jan Anders Vedin
-
Jan Anders Vedin

Chairman

31/12/2015 19/02/2023